PMID- 24363061
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20220317
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 4
DP  - 2014 Apr
TI  - Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal 
      squamous cell carcinoma.
PG  - 3743-53
LID - 10.1007/s13277-013-1496-2 [doi]
AB  - Proliferating cancer cells preferentially use anaerobic glycolysis rather than 
      oxidative phosphorylation for energy production. Hexokinase 2 (HK2) is highly 
      expressed in many malignant cells and is necessary for anaerobic glycolysis. The 
      role of HK2 in laryngeal squamous cell carcinoma (LSCC) is unknown. In this 
      study, the expression of HK2 in LSCC was investigated and the effect of 
      inhibiting HK2 expression with small hairpin RNA (shRNA) on tumor growth was 
      investigated. Using immunohistochemistry, HK2 expression was assessed in LSCC 
      tissues. Human laryngeal carcinoma Hep-2 cells were stably transfected with a 
      plasmid expressing HK2 shRNA (pGenesil-1.1-HK2) and were compared to control 
      cells with respect to the cell cycle, cell viability, apoptosis, and their 
      ability to form xenograft tumors. HK2 expression was significantly higher in LSCC 
      than in papilloma or glottis polypus. Tumor samples of higher T, N, and TNM stage 
      often had stronger HK2 staining. HK2 shRNA reduced HK2 mRNA, protein levels, and 
      HK activity in Hep-2 cells. HK2 cells expressing shRNA demonstrated a higher 
      G0-G1 ratio, increased apoptosis, and reduced viability. Xenograft tumors derived 
      from cells expressing HK2 shRNA were smaller and had lower proliferation than 
      those from untransfected or control-plasmid-transfected cells. In conclusion, 
      depletion of HK2 expression resulted in reduced xenograft tumor development 
      likely by reducing proliferation, altering the cell cycle, reducing cell 
      viability and activating apoptosis. These data suggest that HK2 plays an 
      important role in the development of LSCC and represents a potential therapeutic 
      target for LSCC.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Otorhinolaryngology, Union Hospital of Tongji Medical College, 
      Huazhong University of Science and Technology, Number 1277 Jiefang Avenue, Wuhan, 
      Hubei, China.
FAU - Zhang, Sulin
AU  - Zhang S
FAU - Li, Yuncheng
AU  - Li Y
FAU - Tang, Zhengang
AU  - Tang Z
FAU - Kong, Weijia
AU  - Kong W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131221
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Ki-67 Antigen)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/mortality/*pathology
MH  - Cell Line, Tumor
MH  - *Cell Proliferation
MH  - Glycolysis
MH  - Head and Neck Neoplasms/mortality/*pathology
MH  - Hexokinase/analysis/genetics/*physiology
MH  - Humans
MH  - Ki-67 Antigen/analysis
MH  - Laryngeal Neoplasms/etiology/mortality/*pathology
MH  - Middle Aged
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Xenograft Model Antitumor Assays
EDAT- 2013/12/24 06:00
MHDA- 2014/06/10 06:00
CRDT- 2013/12/24 06:00
PHST- 2013/09/28 00:00 [received]
PHST- 2013/11/28 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - 10.1007/s13277-013-1496-2 [doi]
PST - ppublish
SO  - Tumour Biol. 2014 Apr;35(4):3743-53. doi: 10.1007/s13277-013-1496-2. Epub 2013 
      Dec 21.